Research News – Spring 2020
MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article. FDA Agrees to Expanded Access Program for MDMA-Assisted Therapy for PTSD On December 20, 2019, the U.S. Food and Drug Administration (FDA) …
Bulletin Category: Bulletin: Spring 2020
The Commercial Chemistry of MDMA: From Research to Patient Access
Written by Heather Clouting, M.Sc. MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article. Nearly 20 years ago, during our final year of university while studying for our Bachelor’s in chemistry, …
R/evolutionary Medicine, R/evolutionary Industry: The Role of Conscious Policy and Corporate Structures in Psychedelic Healthcare
Written by the MAPS Policy & Advocacy Department Leslie Booher, J.D./M.B.A (Fellow) Ismail Lourido Ali, J.D. (Counsel) Natalie Lyla Ginsberg, M.S.W (Director) MAPS Bulletin Spring 2020: Vol. 30, No. …
The Unified Field Theory of Psychedelic Integration and Portugal Style Decriminalization
Written by David Bronner MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article. How non-profit psychedelic drug development harmonizes with efforts to decriminalize plant medicines and legalize …
Sage Institute: A Model for Accessible Psychedelic Therapy and Training
Written by Genesee Herzberg, Psy.D and Heather Valdez, L.C.S.W. MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article. As psychedelic medicine enters the mainstream, moving towards legalization, …
Promise, Power, and Profit: The Economics of Ketamine Treatment
Written by Raquel Bennett, Psy.D. and Alexander Belser, Ph.D. MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article. There has been a recent explosion of interest in ketamine, a synthetic chemical …
The FDA and Psychedelic Drug Development: Working Together to Make Medicines
Written by Victoria Hale, Ph.D. MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article. The Multidisciplinary Association for Psychedelic Studies (MAPS), the Usona Institute, and Compass Pathways …
Psychedelic Medicalization: How Do We Get It Right?
Written by Greg Kearns MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article. As clinical trials for the use of medicines like MDMA and psilocybin in psychedelic-assisted psychotherapy (PAT) …
The Pollination Approach to Delivering Psychedelic-Assisted Mental Healthcare
Written by Bennet A. Zelner MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article. In this article I outline a novel economic approach for delivering psychedelic-assisted mental healthcare, the …
A North Star for the Emerging Psychedelics Industry
Written by Liana Sananda Gillooly and Kat Conour MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article. The field of psychedelics is rapidly expanding, with a Cambrian explosion of new entities …
Expanding Ancestral Knowledge Beyond the Sale of Molecules: Iboga and Ibogaine in the Context of Psychedelic Commercialization
Written by Ricard Faura, Ph.D, Andrea Langlois, and José Carlos Bouso, Ph.D. MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article. From Gabon to all corners of the globe, practices with iboga …
The Commercialization of Ibogaine to Treat Substance Use Disorders and Other Psychiatric Conditions in the United States: A Doctor’s View
MAPS Bulletin Spring 2020: Vol. 30, No. 1 Download this article.